REDWOOD CITY, Calif.,
March 27, 2018 /PRNewswire/
-- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx" or
the "Company"), a specialty pharmaceutical company focused on
innovative therapies for use in medically supervised settings,
today announced the appointment of John
Saia as General Counsel, effective April 16, 2018. Mr. Saia joins AcelRx from
McKesson Corporation, a global leader in healthcare supply chain
management solutions, retail pharmacy, community oncology and
specialty care, and healthcare information technology.
"John brings substantial experience as a healthcare executive
with expertise in corporate development, corporate governance,
regulatory compliance, and securities law to the leadership team,"
said Vince Angotti, AcelRx's Chief
Executive Officer. "John's appointment comes at an important
time for AcelRx, as we prepare to resubmit our DSUVIA NDA and begin
preparation for an expected FDA advisory committee meeting, with an
anticipated PDUFA date later this year. John's extensive
experience and leadership will be highly valued."
Mr. Saia has over a decade of healthcare industry experience and
joins AcelRx from McKesson Corporation, where he most recently
served as its Corporate Secretary and Associate General
Counsel. At McKesson, he served in various roles with
increasing responsibilities and leadership, which included leading
and supporting nearly 100 acquisitions over this time period.
Prior to McKesson, Mr. Saia was a senior attorney at DLA Piper,
advising clients on capital markets transactions, public reporting
and M&A. Earlier in his career, Mr. Saia was an attorney
and special counsel at the U.S. Securities and Exchange
Commission.
"AcelRx has an experienced leadership team that has made
significant strides towards getting DSUVIA approved by the FDA,"
said Mr. Saia. "I look forward to working alongside the talented
team at AcelRx to deliver medicine that has the potential to change
the current standard of care in medically supervised settings."
Mr. Saia received his law degree from The George Washington University Law School and
bachelor's degree from Santa Clara
University.
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company
focused on the development and commercialization of innovative
therapies for use in medically supervised settings. AcelRx's
proprietary, non-invasive sublingual formulation technology
delivers sufentanil with consistent pharmacokinetic profiles. The
Company has two product candidates including DSUVIA™
(sufentanil sublingual tablet, 30 mcg), known as DZUVEO outside
the United States, with a proposed
indication for the treatment of moderate-to-severe acute pain in
medically supervised settings, and Zalviso® (sufentanil
sublingual tablet system, SST system, 15 mcg) being developed as an
innovatively designed patient-controlled analgesia (PCA) system for
reduction of moderate-to-severe acute pain in medically supervised
settings.
For additional information about AcelRx's clinical programs,
please visit www.acelrx.com.
View original content with
multimedia:http://www.prnewswire.com/news-releases/acelrx-announces-appointment-of-john-saia-as-general-counsel-300619734.html
SOURCE AcelRx Pharmaceuticals, Inc.